Our track leads are hard at work shaping the scientific programme for IAS 2025, the 13th IAS Conference on HIV Science – and we are excited to share with you some of the key science they are looking forward to!
This biennial conference presents the latest HIV research and innovations that move science into policy and practice.
Abstracts to look out for, chosen by our track leads:
Track A: Basic science
- “Impact of BCG vaccination on innate immune responses in HIV-exposed infants who have not acquired HIV: A randomized controlled trial in Uganda”, a comparison of the trained immune response in HIV-1-exposed infants who received the BCG vaccination at birth and those who received it at 14 weeks
- “HLA-E restricted HIV-1 TCR transductants efficiently reduce the size of the HIV reservoir”, an examination of the ability of HLA-E restricted T cells to suppress HIV-1 replication in humanized mice, utilizing a T cell receptor-based immunotherapy approach
- “Altered viral rebound dynamics in chronically treated people with HIV given long-acting broadly neutralizing antibodies and N-803”, with preliminary results of the antiviral activity of the combination of two long-acting bNAbs and N-803 in people living with HIV during ATIs
- “Unique cellular signatures and HIV transcripts identified in CD4 lymphoid T cells: HOPE Act organ transplantation collaboration”, the results of which can inform efforts to target and eliminate HIV-harbouring cells
Track B: Clinical science
- “Pharmacokinetic modelling to support WHO-weight band dosing of the new paediatric darunavir/ritonavir (120/20 mg) fixed-dose combination tablet for children”, reporting on a pharmacokinetic modelling/simulation study to work out the best DRV/r dosing for children aged three years and older within the WHO weight bands
- “Pregnancy and neonatal outcomes following prenatal exposure to cabotegravir (CAB): data from The Antiretroviral Pregnancy Registry (APR)”, with preliminary data investigating whether prenatal exposure to long-acting injectable cabotegravir is safe for pregnant people and their newborns
- “Predictors of weight gain among people living with HIV over 3-year period”, a demonstration of the relative contribution of ART to weight gain by age, immune profile and regimen in people living with HIV
Track C: Epidemiology and prevention science
- “Inclusion of pregnant and lactating people in the PURPOSE 1 study: Efficacy, safety and pharmacokinetics”, reporting on the first PrEP trial to intentionally include pregnant and lactating people to advance understanding of safety and efficacy of lenacapavir for this population and their infants
- “Choices in motion: How young people in the PrEPared to Choose study (Cape Town, South Africa) navigate PrEP product switching”, reporting on an implementation study allowing for unscheduled product switching between three PrEP formulations (oral PrEP, CAB-LA and the dapivirine vaginal ring)
Track D: Social and behavioural sciences
- “AI-powered preventive intervention for stigma and suicidal ideation in HIV self-management: Development, evaluation and user testing of the MARVIN chatbot’s integrated mental health management module”, showing how a chatbot can support HIV self-management by providing knowledge and adherence support
- “Stigma leads to substance use among men who have sex with men and trans women living with HIV: Insights from Vietnam”, reporting on a prospective cohort study to assess the association between stigma and subsequent use of opiates and amphetamine-type stimulants among these populations in Vietnam.
Track E: Implementation science, economics, systems and synergies
- “Innovative use of mobile digital chest X-ray equipped with artificial intelligence to improve TB diagnosis among people living with HIV at primary health centres in Lagos, Nigeria”, highlighting the potential of using digital and AI to enhance effectiveness of TB/HIV service integration in primary healthcare
- “Decentralizing HIV care: Blockchain solutions for client data integrity and pharmaceutical supply chain resilience”, reporting how blockchain solutions can improve HIV care by addressing critical challenges in data management and pharmaceutical supply chains
- “Continuity on long-acting cabotegravir (CAB-LA) for HIV pre-exposure prophylaxis (PrEP): A comparison of naive and experienced clients in Zambia”, presenting on the USAID DISCOVER-Health project providing CAB-LA to naive and experienced clients transitioning from oral PrEP
- “Transformative harm reduction and empowerment strategies for people who use drugs: Community-centric innovations in South Africa”, detailing interventions to reduce transmissions through injecting drug use, promote human rights and support socioeconomic empowerment of people who use drugs
Register for the world’s most influential meeting on HIV research and its applications! IAS 2025 takes place in Kigali, Rwanda, and virtually from 13 to 17 July, with pre-conferences on 13 July.
The conference offers an opportunity for scientists, policy makers and activists to come together to inform, engage and inspire urgent global action to chart a new and equitable path forward.
Join thousands across the globe uniting to shape the future of the HIV response.